BioInvent International
Develops novel, first-in-class immuno-modulatory antibodies for cancer therapy.
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Manufacturing
Description
BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-25 10:00 |
Kallelse till årsstämma i BioInvent International AB
|
Swedish | 108.0 KB | ||
| 2025-02-27 08:00 | Swedish | 3.0 MB | |||
| 2025-02-27 08:00 | English | 3.0 MB | |||
| 2025-01-08 08:00 |
BioInvent announces promising initial efficacy data from triple combination arm…
|
English | 85.2 KB | ||
| 2025-01-08 08:00 |
BioInvent tillkännager lovande initiala effektdata från trippelkombinationsarme…
|
Swedish | 85.1 KB | ||
| 2025-01-08 08:00 |
BioInvent announces promising initial efficacy data from triple combination arm…
|
English | 85.2 KB | ||
| 2025-01-08 08:00 |
BioInvent tillkännager lovande initiala effektdata från trippelkombinationsarme…
|
Swedish | 85.1 KB | ||
| 2025-01-08 07:57 |
BioInvent tillkännager lovande data för BI-1910 som monoterapi från fas 1-studi…
|
Swedish | 82.4 KB | ||
| 2025-01-08 07:57 |
BioInvent announces promising data for BI-1910 as single agent from Phase 1 stu…
|
English | 82.0 KB | ||
| 2024-10-31 08:02 | Swedish | 3.0 MB | |||
| 2024-10-31 08:00 | English | 3.0 MB | |||
| 2024-09-09 07:15 |
BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808…
|
English | 84.6 KB | ||
| 2024-09-09 07:15 |
BioInvent meddelar ytterligare positiva effektdata från anti-TNFR2 fas 2a-progr…
|
Swedish | 85.8 KB | ||
| 2024-08-29 08:00 | Swedish | 3.1 MB | |||
| 2024-08-29 08:00 | English | 3.0 MB |
Automate Your Workflow. Get a real-time feed of all BioInvent International filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioInvent International
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioInvent International via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
Peer Companies
